P-0005 - Clinicopathological significance of expression of beclin1 and p62 in gastric cancer
|Date||28 June 2014|
|Event||World GI 2014|
|Topics|| Gastric Cancer
|Citation||Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165|
F. Gu1, X. Yan2
Beclin1 and p62 are both very important regulatory factors in autophagy, which is a hot topic in recent years. Our study aimed to investigate the clinicopathological significance of expression of beclin1 and p62 in gastric cancer (GC), and to analyze the correlation between their expression and the prognosis of patients with GC.
Three hundred and four cases of surgically resected gastric cancer tissue specimens with paired normal gastric mucosa were collected. The immunohistochemistry and Western blot were used to detect the expression of beclin1 and p62.
The positive rate of beclin1 in GCs was significantly lower than that in normal gastric mucosa (66.12%, 201/304 vs.90.79%, 276/304), P = 0.016. Compared with in normal gastric mucosa, the positive rate of p62 in gastric cancer (77.96%, 237/304) was statistically increased. Beclin1 expression was negatively related to p62 expression (rk = 0.122, P = 0.033). Semi-quantitative analysis of beclin1 and p62 in gastric cancer confirmed the result of the immunohistochemistry. Patients with beclin1 positive tumors showed significantly better prognosis than that with beclin1 negative ones (56.192 ± 3.486 vs.31.452 ± 2.514m), P < 0.001. While, patients with p62 positive tumors underwent significantly worse outcome than that with p62 negative ones (39.491 ± 2.987 vs.59.207 ± 5.735m), P = 0.011.
Both beclin1 positive expression and p62 negative expression along with better prognosis may be related to that the former can induce autophagy and the latter can take part in autophagy of tumor cells. Thus, beclin1 and p62 are likely to be hopeful and important prognosis factors for gastric cancer.